Drug Profile


Alternative Names: 2190915; AM 803; GSK-2190915; GSK-2190915A; GSK-2190915B

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Amira Pharmaceuticals
  • Developer Amira Pharmaceuticals; GlaxoSmithKline
  • Class Antiasthmatics; Small molecules
  • Mechanism of Action 5-lipoxygenase activating protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Asthma
  • Discontinued Cardiovascular disorders

Most Recent Events

  • 28 Aug 2015 No recent reports of development identified - Phase-II for Asthma (Adjunctive treatment) in Poland, Ukraine, Bulgaria, USA, United Kingdom and Canada (PO)
  • 28 Aug 2015 No recent reports of development identified - Phase-II for Asthma in Ukraine, European Union, Japan and USA (PO)
  • 24 Jul 2013 Phase II development is ongoing for Asthma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top